Gastroenterologyclinical trialsgastroenterology
Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores
By MedXY|Feb 4, 2026
A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul
